Trilaciclib

Drug Profile

Trilaciclib

Alternative Names: G1T 28; G1T28-1

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator G1 Therapeutics
  • Class Antineoplastics; Chemoprotectants; Cyclohexanes; Piperazines; Pyrazines; Pyridines; Pyrimidines; Pyrimidinones; Pyrroles; Radioprotectives; Small molecules; Spiro compounds
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Small cell lung cancer
  • Phase I Cancer; Myelosuppression

Most Recent Events

  • 24 May 2017 Chemical structure information added
  • 07 Apr 2017 Phase-II clinical trials in Small cell lung cancer (Combination therapy, First-line therapy, Newly diagnosed) in USA (IV) (NCT03041311)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top